ARTICLE | Company News
ID Biomedical, National Institutes of Health deal
October 11, 2004 7:00 AM UTC
IDB received a $5.6 million grant from the NIH to use its Proteosome mucosal adjuvant/delivery technology to develop a nasally delivered subunit vaccine against SARS. Last month, the NIH awarded IDB ...